Goldman Sachs-backed drug developer Septerna said on Thursday it was seeking a valuation of $743.1 million in its upsized ...
**NM signifies a non meaningful value. A dash signifies the data is not available.
The fund’s top 10 holdings account for 57% of its assets and include names like Novo Nordisk (7.4%), ASML Holdings (6.7% ... A shares are listed on the Toronto Stock Exchange under the symbols GCG and ...
The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...
Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...
Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition ...
A Watertown biotech says is received a $112 million investment led by the investment firm that manages the assets of the Novo ...
Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat ...
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too.
After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel hemophilia treatment concizumab. Meanwhile, PTC Therapeutics' troubled ...
In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks discussed by Jim Cramer during the latest lightning round. On Tuesday, Jim Cramer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback